文献类型：期刊文献

英文题名：Efficacy and safety of montelukast adjuvant therapy in adults with cough variant asthma: A systematic review and meta-analysis

作者：Xu, Qian[1,2,3];Lu, Tingting[2,3];Song, Zhongyang[4];Zhu, Peng[1];Wu, Yana[1];Zhang, Lumei[1];Yang, Kehu[2,3];Zhang, Zhiming[5]

第一作者：徐芹;Xu, Qian

通信作者：Yang, KH[1];Zhang, ZM[2]

机构：[1]Gansu Univ Chinese Med, Clin Coll Tradit Chinese Med, Lanzhou, Gansu, Peoples R China;[2]Gansu Prov Hosp, Inst Clin Res & Evidence Based Med, Lanzhou, Gansu, Peoples R China;[3]Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou 730000, Gansu, Peoples R China;[4]Gansu Univ Chinese Med, Gansu Prov Canc Clin Res Ctr Integrated Tradit Chi, Affiliated Hosp, Lanzhou, Gansu, Peoples R China;[5]Gansu Prov Hosp Tradit Chinese Med, Lanzhou 730050, Gansu, Peoples R China

第一机构：甘肃中医药大学中医临床学院

通信机构：[1]corresponding author), Lanzhou Univ, Evidence Based Med Ctr, Sch Basic Med Sci, Lanzhou 730000, Gansu, Peoples R China;[2]corresponding author), Gansu Prov Hosp Tradit Chinese Med, Lanzhou 730050, Gansu, Peoples R China.

年份：2023

卷号：17

期号：10

起止页码：986

外文期刊名：CLINICAL RESPIRATORY JOURNAL

收录：;Scopus(收录号：2-s2.0-85159892051);WOS:【SCI-EXPANDED(收录号:WOS:000991263900001)】；

语种：英文

外文关键词：cough variant asthma; meta-analysis; montelukast; randomized controlled trial

摘要：Background: Montelukast is a highly selective and specific cysteinyl leukotriene receptor antagonist used in the treatment of asthma. Whether montelukast as adjuvant therapy can significantly and safely treat adults with cough variant asthma (CVA) remains inconclusive. Aims: This meta-analysis systematically evaluated the efficacy and safety of montelukast as an adjuvant treatment for adults with CVA. Materials and methods: Randomized controlled trials (RCTs) on montelukast combined with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABAs) to treat CVA in adults, from inception to March 6, 2023, were retrieved from the CNKI, Wanfang, VIP, CBM, PubMed, Embase, Cochrane Library, and Web of Science databases and Clinical Trials website. Review Manager (version 5.4) and Stata (version 15.0) were used to conduct the meta-analysis. Results: A total of 15 RCTs were ultimately included in the meta-analysis. It was established that montelukast as adjuvant therapy raised the total effective rate (RR = 1.20, 95% confidence interval [CI] [1.13, 1.27], P < 0.01) and improved the FEV1% (SMD = 0.91, 95% CI [0.40, 1.41], P < 0.01), PEF% (SMD = 0.63, 95% CI [0.38, 0.88], P < 0.01), FEV1 (SMD = 1.15, 95% CI [0.53, 1.77], P < 0.01), PEF (SMD = 0.64, 95% CI [0.42, 0.86], P < 0.01), and FEV1/FVC% (SMD = 0.76, 95% CI [0.51, 1.01], P < 0.01) and reduced the recurrence rate (RR = 0.28, 95% CI [0.15, 0.53], P < 0.01). The incidence of adverse reactions was higher in the montelukast auxiliary group compared to the control group but with no statistical difference (RR = 1.32, 95% CI [0.89, 1.96], P = 0.17). Conclusion: Existing evidence indicated that the use of montelukast as an adjuvant therapy had therapeutic efficacy superior to ICS + LABA alone for the treatment of adult patients with CVA. However, further research is needed, especially a combination of high-quality long-term prospective studies and carefully designed RCTs.